Predictive value of biomarkers in immunotherapy of advanced non-small cell lung cancer

VernacularTitle:生物标志物在晚期非小细胞肺癌免疫治疗中的预测价值
Author: Yan LEI ¹ ; Gehong ZHANG
Author Information

1. 山西医科大学第一临床医学院，太原　030001
Keywords: Carcinoma, non-small-cell lung; Immune checkpoint inhibitors; Biomarker
From: Journal of International Oncology 2022;49(12):739-744
CountryChina
Language:Chinese
Abstract: Immunotherapy, especially immune checkpoint inhibitor, has revolutionized the treatment mode of advanced non-small cell lung cancer. The predictive effect of programmed death-ligand 1 and tumor mutation burden for treatment response has been fully proved. Neither of which can avoid some problems, including tumor heterogeneity, inconsistent detection methods and identification standards. The studies have found that some novel biomarkers are related to the efficacy of immunotherapy, such as mismatch repair deficiency and microsatellite instability, driver gene mutation, routine peripheral blood biomarkers, circulating tumor cells, circulating tumor DNA and so on. Further research on the predictive value of biomarkers in tumor tissue and peripheral blood in immunotherapy of advanced non-small cell lung cancer can provide a reference for instituting clinical treatment plan.